HSPA9 and cancer: SHetA2 (NSC 726189), a small-molecule drug that disrupts mortalin/p53 complexes in ovarian cancer cells (Ramraj et al., 2020), is currently being developed for clinical applications based on its induction of apoptosis in cancer cells, whereas its effect on healthy cells is limited to G1 cell cycle arrest (Guruswamy et al., 2001; Liu et al., 2009; Masamha and Benbrook, 2009).